JAK inhibitors

alopecia hair loss
Biotech

Q32’s stock jumps 60% on latest phase 2 alopecia data

The phase 2 readout drew investor enthusiasm, supporting the biotech’s claim that the drug could offer a more durable alternative to JAK inhibitors.
James Waldron Jul 13, 2026 10:40am
Lilly

Lilly’s $2.3B Ajax drug works ‘right out of the gate’

Jun 13, 2026 11:15am
photo of a pair of hands that show the skin condition vitiligo

Incyte’s vitiligo bet scores ph. 3 wins but can’t shake off Rinvoq

Apr 28, 2026 9:52am
Eli Lilly booth at AACR 2026

Lilly pens $2.3B deal for next-gen JAK inhibitor biotech Ajax

Apr 27, 2026 8:25am
Sanofi
Favicon Fierce Pharma

Sanofi inks $1.5B deal for Sino Biopharm's novel asset

Mar 4, 2026 3:00am
Close up shot of the target from a dart game

Lynk sees ph. 3 eczema win as proof of JAK inhibitor's potential

Mar 2, 2026 8:55am